EUCTR2012-002555-42-BE进行中（未招募）不适用
A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435 with and without GSK2336805 with a pharmacokinetic enhancer with and without ribavirin in chronic genotype 1 hepatitis C infected patients
Janssen R&D Ireland0 个研究点开始时间: 2012年6月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Documented chronic genotype 1a or genotype 1b hepatitis C virus (HCV) infection with HCV RNA level >100,000 IU/mL at screening
- •- Treatment-naive, documented prior relapse or null responder to previous treatment regimens and has stopped treatment at least 3 months before screening
- •- Liver biopsy within 3 years before the screening visit or elastography results availabe prior to first study drug dosing
- •- Medically stable based on physical examination, medical history, vital signs, and electrocardiogram performed at screening
- •- Body mass index of 18.0 to 32.0 kg/m2 and body weight >50 kg
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 82
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •-Evidence of liver cirrhosis by liver biopsy or the presence of esophageal varices or a transient elastography result of >14.6 kPa within 2 years prior to first dosing
- •- Evidence of decompensated liver disease defined as prior history or current evidence of ascites, hepatic encephalopathy, bleeding oesopaghal or gastric varices
- •- Evidence of any significant liver disease in addition to hepatitis C (including but not limited to hepatitis B, drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson’s disease, non-alcoholic steatohepatitis, or primary biliary cirrhosis)
- •- Receiving or has received any HCV-specific direct antiviral agent (HCV protease inhibitors, HCV nucleoside polymerase inhibitors, HCV non-nucleoside polymerase inhibitors, HCV NS5a inhibitors or any other HCV inhibitor targeting an HCV protein or a target involved in the HCV replication cycle
- •- Has participated in another clinical trial with an investigational drug, vaccine or device within 90 days prior to screening
- •- Co-infected with human immunovirus (HIV)-1 or HIV-2, with non-genotype 1a/1b HCV, or hepatitis A or B virus infection
- •- Any cardiac disease at screening, or any active clinical significant disease, or medical history or physical examination findings during screening that, in the investigator’s opinion, could compromise the outcome of the trial
- •- History or evidence of current abuse of alcohol (5 glasses/day during 5 years), barbiturate, amphetamine, recreational or narcotic drug use, which in the investigator’s opinion would compromise subject’s safety and/or compliance with the study procedures
- •- Positive urine drug (with exclusion of methadone or equivalent) test at study screening
- •- Protocol-specified laboratory values
- •- Liver transplant, or any organ/tissue transplant
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, and Efficacy of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK2336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype-1 Hepatitis C Infected PatientsChronic hepatitis C-infected patientsMedDRA version: 17.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-002555-42-DEJanssen R&D Ireland86
进行中（未招募）
不适用
A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents. - Pediatric trial with Intelence as an Active NNRTI Option (PIANO)HIV-1 infectionMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2007-007086-21-BETibotec Pharmaceuticals100
进行中（未招募）
不适用
A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents - NDHIV-1 INFECTIONMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2007-007086-21-ITTIBOTEC PHARMACEUTICALS LTD.100
进行中（未招募）
1 期
A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents. - Pediatric trial with Intelence as an Active NNRTI Option (PIANO)EUCTR2007-007086-21-GBTibotec Pharmaceuticals101
进行中（未招募）
不适用
A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents. - Pediatric trial with Intelence as an Active NNRTI Option (PIANO)EUCTR2007-007086-21-PTTibotec Pharmaceuticals100